C3 glomerulopathy: Consensus report

Matthew C. Pickering, Vivette D. D'agati, Carla M. Nester, Richard J. Smith, Mark Haas, Gerald B. Appel, Charles E. Alpers, Ingeborg M. Bajema, Camille Bedrosian, Michael Braun, Mittie Doyle, Fadi Fakhouri, Fernando C. Fervenza, Agnes B. Fogo, Véronique Frémeaux-Bacchi, Daniel P. Gale, Elena Goicoechea De Jorge, Gene Griffin, Claire L. Harris, V. Michael HolersSally Johnson, Peter J. Lavin, Nicholas Medjeral-Thomas, B. Paul Morgan, Cynthia C. Nast, Laure Hélène Noel, D. Keith Peters, Santiago Rodríguez De Córdoba, Aude Servais, Sanjeev Sethi, Wen Chao Song, Paul Tamburini, Joshua M. Thurman, Michael Zavros, H. Terence Cook

Research output: Contribution to journalArticlepeer-review

327 Scopus citations


C3 glomerulopathy is a recently introduced pathological entity whose original definition was glomerular pathology characterized by C3 accumulation with absent or scanty immunoglobulin deposition. In August 2012, an invited group of experts (comprising the authors of this document) in renal pathology, nephrology, complement biology, and complement therapeutics met to discuss C3 glomerulopathy in the first C3 Glomerulopathy Meeting. The objectives were to reach a consensus on: the definition of C3 glomerulopathy, appropriate complement investigations that should be performed in these patients, and how complement therapeutics should be explored in the condition. This meeting report represents the current consensus view of the group.

Original languageEnglish (US)
Pages (from-to)1079-1089
Number of pages11
JournalKidney international
Issue number6
StatePublished - Dec 2013


  • clinical immunology
  • clinical nephrology
  • complement
  • glomerulonephritis
  • immunology and pathology

ASJC Scopus subject areas

  • Nephrology


Dive into the research topics of 'C3 glomerulopathy: Consensus report'. Together they form a unique fingerprint.

Cite this